Evogene Ltd Stock Other OTC
Equities
IL0011050551
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jun. 20 | Nir Arbel Steps Down as Chief Product Officer of Evogene Ltd | CI |
May. 23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
Financials (USD)
Sales 2024 * | 14.99M | Sales 2025 * | 25.85M | Capitalization | 31.89M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -19M | EV / Sales 2024 * | 2.13 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.23 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Evogene Ltd
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |